Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioXcel Therapeutics Inc BTAI

Healthcare Biotechnology
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation... see more

Recent & Breaking News (NDAQ:BTAI)

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

GlobeNewswire November 22, 2024

BioXcel Therapeutics Announces Proposed Public Offering

GlobeNewswire November 21, 2024

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

GlobeNewswire November 14, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia

GlobeNewswire November 12, 2024

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

GlobeNewswire November 8, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference

GlobeNewswire October 29, 2024

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

GlobeNewswire October 15, 2024

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

GlobeNewswire September 19, 2024

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

GlobeNewswire September 5, 2024

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

GlobeNewswire August 7, 2024

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

GlobeNewswire August 6, 2024

BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

GlobeNewswire July 30, 2024

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI(TM) (dexmedetomidine) Sublingual Film

GlobeNewswire July 16, 2024

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI(TM) (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

GlobeNewswire June 25, 2024

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

GlobeNewswire May 28, 2024

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

GlobeNewswire May 21, 2024

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

GlobeNewswire May 9, 2024

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire April 25, 2024

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

GlobeNewswire April 24, 2024

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

GlobeNewswire April 22, 2024